The Chemours Company (NYSE:CC - Get Free Report)'s share price fell 5.9% on Thursday . The stock traded as low as $14.36 and last traded at $14.16. 335,393 shares were traded during mid-day trading, a decline of 90% from the average session volume of 3,452,607 shares. The stock had previously closed at $15.04.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on CC. Royal Bank Of Canada lifted their target price on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Thursday, July 3rd. Zacks Research raised shares of Chemours from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Mizuho lifted their target price on shares of Chemours from $16.00 to $19.00 and gave the company an "outperform" rating in a research note on Tuesday, September 23rd. UBS Group lifted their target price on shares of Chemours from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Monday. Finally, Truist Financial lifted their target price on shares of Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $18.13.
Get Our Latest Research Report on CC
Chemours Stock Down 8.5%
The firm has a market cap of $2.06 billion, a P/E ratio of -4.91 and a beta of 1.65. The business's fifty day moving average price is $15.13 and its two-hundred day moving average price is $13.01. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16.
Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business's revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.
Chemours Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Friday, August 15th. Chemours's dividend payout ratio (DPR) is presently -12.50%.
Insider Transactions at Chemours
In other news, CEO Denise Dignam acquired 4,068 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $12.06 per share, with a total value of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Chemours
Several institutional investors have recently bought and sold shares of CC. UMB Bank n.a. raised its holdings in shares of Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 948 shares during the last quarter. Yousif Capital Management LLC raised its stake in shares of Chemours by 1.6% in the second quarter. Yousif Capital Management LLC now owns 62,386 shares of the specialty chemicals company's stock worth $714,000 after acquiring an additional 968 shares during the last quarter. Man Group plc raised its stake in shares of Chemours by 0.4% in the second quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company's stock worth $3,104,000 after acquiring an additional 979 shares during the last quarter. CWM LLC raised its stake in shares of Chemours by 34.7% in the second quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company's stock worth $49,000 after acquiring an additional 1,104 shares during the last quarter. Finally, Brown Advisory Inc. raised its stake in shares of Chemours by 6.0% in the first quarter. Brown Advisory Inc. now owns 20,874 shares of the specialty chemicals company's stock worth $282,000 after acquiring an additional 1,174 shares during the last quarter. Institutional investors own 76.26% of the company's stock.
About Chemours
(
Get Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.